Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL
GLOBETECH PUBLISHING LLC

New Strategy Could Thwart Periodontal Disease Progress

By BiotechDaily International staff writers
Posted on 02 Jan 2013
A new study suggests that blocking a specific molecular receptor on white blood cells (WBCs) could prevent periodontitis from developing, as well as halting the progression of the disease once it has already developed.

Researchers at the University of Pennsylvania (Penn, Philadelphia, USA) showed (in a mouse model) that Porphyromonas gingivalis--the bacterium responsible for many cases of periodontitis--acts by “hijacking” a receptor on WBCs called C5aR, which is part of the complement system, a component of the immune system that helps clear infection but can trigger damaging inflammation if improperly controlled. By hijacking C5aR, P. gingivalis subverts the complement system and handicaps immune cells, rendering them less able to clear infection from the gum tissue, resulting in severe inflammation.

Other studies have shown that toll-like receptors (TLRs, a set of proteins that also activate immune cell responses) may also act in concert with the complement system; in fact, mice that are C5aR-deficient and those lacking TLR2 do not develop bone loss. The researchers therefore tried to determine if the synergism seen between the complement system and TLRs was also at play in inflammatory gum disease. To find out, they injected two types of molecules, one that activated C5aR and another that activated TLR2, into the gums of mice. When only one type of molecule was administered, a moderate inflammatory response became apparent, but when injected together, inflammatory molecules increased dramatically.

In fact, the inflammatory molecules soared to levels higher than would have been expected if the effect of activating both receptors was merely additive. The finding suggested to the scientists that the TLR signaling was somehow involved in "crosstalk" with the complement system, serving to augment the inflammatory response. They then surmised that blocking one of the receptors could effectively halt the inflammation that allows P. gingivalis and other bacteria to thrive and cause disease.

To test the hypothesis, the researchers synthesized and administered a molecule that blocks the activity of C5aR to mice that were then infected with P. gingivalis. Subsequent C5aR antagonist injections were able to stave off inflammation to a large extent, reducing inflammatory molecules by 80% and completely stopping bone loss. Similar effects were seen when the mice were given the antagonist two weeks after being infected, reducing signs of inflammation by 70% and inhibiting nearly 70% of periodontal bone loss. The study was published in the Journal of Immunology.

“Regardless of whether we administered the C5a receptor antagonist before the development of the disease or after it was already in progress, our results showed that we could inhibit the disease either in a preventive or a therapeutic mode,” said senior author Professor George Hajishengallis, DDS, PhD.

Related Links:

University of Pennsylvania




Channels

Genomics/Proteomics

view channel
Image: Researchers have generated disease-free stem cells from patients with mitochondrial disease that can be converted into any cell type including neuronal progenitors (left) or heart cells (right). These could potentially be used for future transplantation into patients (Photo courtesy of Salk Institute of Biological Studies).

Methods Developed to Generate Normal Stem Cells from Patients with Mitochondrial Defects

A recent paper described two methods for converting cells from patients with mitochondrial defects into normal pluripotent stem cells that could be induced to differentiate into several different types of tissues.... Read more

Drug Discovery

view channel
Image: A new micelle delivery system for the protective polyphenols resveratrol and quercetin (mRQ) may have value in cancer chemotherapy (Photo courtesy of Oregon State University).

Micelles Containing Resveratrol and Quercetin Reverse Doxorubicin Cardiotoxicity

Cancer researchers blocked the toxic effects of the cancer drug doxorubicin (DOX) by administering it together with the plant antioxidants resveratrol and quercetin. Although in use for more than 40... Read more

Lab Technologies

view channel
Image: The Leica DM2500 LED Microscope for clinical laboratories and research applications (Photo courtesy of Leica Microsystems).

New LED Microscope Completes Line of Clinical and Research Tools

A popular microscope used for both clinical and research applications is now available with LED illumination. The Leica (Wetzlar, Germany) DM2500 and DM2500 LED microscopes represent a class of tools... Read more

Business

view channel

Teva Buys Allergan Generic Business Unit

Teva Pharmaceutical Industries (Petah Tikva, Israel) has bought the Allergan (Irvine, CA, USA) generic drugs business for USD 40.5 billion in cash and stock, solidifying its position as the world's largest generic drug maker. Under the terms of the agreement, Teva will pay USD 33.75 billion in cash and USD 6.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.